Inhibition of binding of interferon-gamma to its receptor by salicylates used in inflammatory bowel disease.

5-Aminosalicylic acid (5ASA), 4ASA, their N-acetylated metabolites N-acetyl-5ASA and N-acetyl-4ASA, olsalazine, and colchicine impair interferon-gamma (IFN gamma) induced HLA-DR expression on a colonic cell line, HT-29. The mechanism of this effect is now reported. HT-29 cells were cultured with 50...

Full description

Bibliographic Details
Main Authors: Crotty, B, Rosenberg, WM, Aronson, J, Jewell, D
Format: Journal article
Language:English
Published: 1992
_version_ 1797059450111000576
author Crotty, B
Rosenberg, WM
Aronson, J
Jewell, D
author_facet Crotty, B
Rosenberg, WM
Aronson, J
Jewell, D
author_sort Crotty, B
collection OXFORD
description 5-Aminosalicylic acid (5ASA), 4ASA, their N-acetylated metabolites N-acetyl-5ASA and N-acetyl-4ASA, olsalazine, and colchicine impair interferon-gamma (IFN gamma) induced HLA-DR expression on a colonic cell line, HT-29. The mechanism of this effect is now reported. HT-29 cells were cultured with 50 U/ml IFN gamma with or without drug, and northern blot analysis was performed using a probe for the beta chain of the DR molecule. IFN gamma led to a noticeable increase in HLA-DR mRNA which was attenuated by the drugs. Analysis of the specific binding of increasing concentrations of 125I-IFN gamma by non-linear regression showed a Kd of 1.35 x 10(-10) M and 2.3 x 10(5) binding sites per HT-29 cell. Binding of 125I-IFN gamma was reduced by incubation with increasing concentrations of unlabelled IFN gamma but not with IFN alpha. Incubation with therapeutic concentrations of drugs led to the following reductions in binding: 10 mM 5ASA, 20% (p < 0.001); 10 mM N-acetyl-5ASA, 24% (p < 0.01); 10 mM 4ASA, 21% (p < 0.005); 10 mM N-acetyl-4ASA, 29% (p < 0.001); and 1 mM olsalazine, 29% (p < 0.001). Colchicine (10(-7) M) and 10(-5) M prednisolone had no effect. Incubation with higher concentrations of the drugs revealed a dose-response effect on binding with complete inhibition by 100 mM 4ASA and 10 mM olsalazine, and lesser degrees of inhibition by 100 mM 5ASA, N-acetyl-5ASA, and N-acetyl-4ASA. At concentrations found in the rectal lumen, the salicylates used in inflammatory bowel disease impair the binding of IFN gamma to its receptor on colonic epithelial cells.
first_indexed 2024-03-06T20:04:26Z
format Journal article
id oxford-uuid:2874800e-7957-4a92-80bd-f5d7198ca741
institution University of Oxford
language English
last_indexed 2024-03-06T20:04:26Z
publishDate 1992
record_format dspace
spelling oxford-uuid:2874800e-7957-4a92-80bd-f5d7198ca7412022-03-26T12:12:52ZInhibition of binding of interferon-gamma to its receptor by salicylates used in inflammatory bowel disease.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:2874800e-7957-4a92-80bd-f5d7198ca741EnglishSymplectic Elements at Oxford1992Crotty, BRosenberg, WMAronson, JJewell, D5-Aminosalicylic acid (5ASA), 4ASA, their N-acetylated metabolites N-acetyl-5ASA and N-acetyl-4ASA, olsalazine, and colchicine impair interferon-gamma (IFN gamma) induced HLA-DR expression on a colonic cell line, HT-29. The mechanism of this effect is now reported. HT-29 cells were cultured with 50 U/ml IFN gamma with or without drug, and northern blot analysis was performed using a probe for the beta chain of the DR molecule. IFN gamma led to a noticeable increase in HLA-DR mRNA which was attenuated by the drugs. Analysis of the specific binding of increasing concentrations of 125I-IFN gamma by non-linear regression showed a Kd of 1.35 x 10(-10) M and 2.3 x 10(5) binding sites per HT-29 cell. Binding of 125I-IFN gamma was reduced by incubation with increasing concentrations of unlabelled IFN gamma but not with IFN alpha. Incubation with therapeutic concentrations of drugs led to the following reductions in binding: 10 mM 5ASA, 20% (p < 0.001); 10 mM N-acetyl-5ASA, 24% (p < 0.01); 10 mM 4ASA, 21% (p < 0.005); 10 mM N-acetyl-4ASA, 29% (p < 0.001); and 1 mM olsalazine, 29% (p < 0.001). Colchicine (10(-7) M) and 10(-5) M prednisolone had no effect. Incubation with higher concentrations of the drugs revealed a dose-response effect on binding with complete inhibition by 100 mM 4ASA and 10 mM olsalazine, and lesser degrees of inhibition by 100 mM 5ASA, N-acetyl-5ASA, and N-acetyl-4ASA. At concentrations found in the rectal lumen, the salicylates used in inflammatory bowel disease impair the binding of IFN gamma to its receptor on colonic epithelial cells.
spellingShingle Crotty, B
Rosenberg, WM
Aronson, J
Jewell, D
Inhibition of binding of interferon-gamma to its receptor by salicylates used in inflammatory bowel disease.
title Inhibition of binding of interferon-gamma to its receptor by salicylates used in inflammatory bowel disease.
title_full Inhibition of binding of interferon-gamma to its receptor by salicylates used in inflammatory bowel disease.
title_fullStr Inhibition of binding of interferon-gamma to its receptor by salicylates used in inflammatory bowel disease.
title_full_unstemmed Inhibition of binding of interferon-gamma to its receptor by salicylates used in inflammatory bowel disease.
title_short Inhibition of binding of interferon-gamma to its receptor by salicylates used in inflammatory bowel disease.
title_sort inhibition of binding of interferon gamma to its receptor by salicylates used in inflammatory bowel disease
work_keys_str_mv AT crottyb inhibitionofbindingofinterferongammatoitsreceptorbysalicylatesusedininflammatoryboweldisease
AT rosenbergwm inhibitionofbindingofinterferongammatoitsreceptorbysalicylatesusedininflammatoryboweldisease
AT aronsonj inhibitionofbindingofinterferongammatoitsreceptorbysalicylatesusedininflammatoryboweldisease
AT jewelld inhibitionofbindingofinterferongammatoitsreceptorbysalicylatesusedininflammatoryboweldisease